Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

us' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals, progress and expected timing of clinical studies, including the progress, timing and design of Phase 3 clinical development for Amigal, the progress and timing of the availability of data from the Phase 2 extension study of Amigal, the progress and timing of Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the timing of the release of data from the Phase 2 clinical trials for Plicera, the initiation of Phase 2 clinical development of AT2220 for the treatment of Pompe disease, and the possibility and timin
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... 2014 This is a professional ... the Epoxy Hardener industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
Breaking Biology Technology:Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... LLC, a clinical-stage drug development company commercializing first-in-class ... completion of a $2.9 million private placement. ... and clinical programs for its lead drug compound, ... David G. Kalergis, Chief Executive Officer of Diffusion ...
... 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China ... CSKI ), a leading,fully integrated pharmaceutical company ... ("PRC"), today announced that the Company,s,Chief Financial Officer, ... meetings at the upcoming Roth 21st Annual OC ...
... Tigris Pharmaceuticals, Inc., a privately held drug development ... Investigational New Drug (IND) application with the U.S. ... novel anticancer compound. GGTI-2418 is a synthetic ... appears to induce apoptosis by downregulating several pivotal ...
Cached Biology Technology:Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 3China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3
(Date:8/29/2014)... of Texas Medical Branch at Galveston has gone on record ... protect monkeys against a lethal dose of Ebola virus up ... disease is severe. , Thomas Geisbert, professor of microbiology and ... advances in Ebola treatment research. The filoviruses known as Ebola ... pathogens, with fatality rates of up to 90 percent. ...
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3
... the observation that a large group of seemingly unconnected ... Now a multi-national research team led by the Melbourne ... has joined the proverbial dots and identified a potential ... paper published today in the prestigious Nature Medicine journal. ...
... (IAA), commonly referred to as auxin, plays a major ... development by affecting the expression of numerous genes that ... in specific plant tissues at specific stages during the ... floral organs to develop in the correct patterns and ...
... them the Dirt Doctors, or Sultans of Soil, they're just ... has a paper in this week's Science Magazine with a ... in the highly complex world beneath our feet. , "Computational ... Soil," by Jason Gans, Murray Wolinsky and John Dunbar, of ...
Cached Biology News:Scientists find microRNAs regulate plant development 2Scientists find microRNAs regulate plant development 3Scientists find microRNAs regulate plant development 4Comparison of Cocaine, Methamphetamine ‘Highs?Finds Differences 2
Schneider's Drosophila - Insect medium...
... and easy operation of a wide range ... The software is fully secure and compliant ... 11 regulations, and compatible with user-created macros ... enables use in high-level research and development ...
... is a proteohormone with a molecular weight of 16 ... ob gene and produced by adipocytes [1,2]. Leptin ... regulation of body weight [1-3]. In the human, ... men and women [4]. A relationship between serum ...
... Components in this kit are prepared ... technology. Biochains Mitochondria Isolation Kit is ... in a fast and easy way. One ... performing 100 isolations (enriching mitochondria from 10 ...
Biology Products: